Page 3 - மேரி பிரான்ஸ் த்ஸ்சுதின் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மேரி பிரான்ஸ் த்ஸ்சுதின். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மேரி பிரான்ஸ் த்ஸ்சுதின் Today - Breaking & Trending Today

Novartis' 2021 access goal: solutions as 'innovative as the science itself'

Feb 8, 2021 9:53am
Novartis pharmaceuticals president Marie-France Tschudin spoke with Fierce Pharma during last month s J.P. Morgan Healthcare Conference.(Vas Narasimhan/Twitter)
Novartis has a busy year ahead with drug launches and pre-launch prep for late-stage pipeline products, but at the same time, the company is making an effort to think differently about improving patient access to its existing medicines, an exec said.
Among its 2021 priorities, the company is examining how to “bring our science to patients in a way that is equally innovative as the science itself, Novartis pharmaceuticals president Marie-France Tschudin said in an interview last month. In the company s treatment areas, only 10% of patients have access to new medicines five years after launch, even in developed countries, Tschudin said. It’s “taking way too long” for patients to get access, she said, noting that the pandemic will likely exacerbate the issue. ....

Marie France Tschudin , Drug Access , மேரி பிரான்ஸ் த்ஸ்சுதின் , மருந்து நுழைவு ,

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis receives positive CHMP opinion for Kesimpta®* (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis

(ofatumumab)
Kesimpta is a targeted, precisely dosed and delivered B-cell therapy that provides the flexibility of self-administration for adults with RMS. It is an anti-CD20 monoclonal antibody (mAb) self-administered by a once-monthly injection, delivered subcutaneously
1,3. Initial doses of Kesimpta are given at Weeks 0, 1 and 2, with the first injection performed under the guidance of a healthcare professional. As shown in preclinical studies, Kesimpta is thought to work by binding to a distinct epitope on the CD20 molecule inducing potent B-cell lysis and depletion
8. The selective mechanism of action and subcutaneous administration of Kesimpta allows precise delivery to the lymph nodes, where B-cell depletion in MS is needed, and preclinical studies have shown that it may preserve the B-cells in the spleen ....

United States , France General , United Kingdom , City Of , Eric Althoff , Isabella Zinck , Thomas Hungerbuehler , Wallstroeme Ofatumumab , Xavier Montalban , Neuroimmunol Neuroinflamm , Samir Shah , Sloan Simpson , Meghan Odonnell , Antonio Ligi , Sclerosis International Federation , Americas Committee For Treatment , Novartis External Communications , Sclerosis Centre Of Catalonia Cemcat , Novartis Pharmaceuticals , Research In Multiple Sclerosis , Committee For Medicinal Products Human Use , Genmab Press , Hebron University Hospital , Drug Administration , European Commission , Novartis Us External Communications ,

Novartis receives positive CHMP opinion for Kesimpta®* (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis

(ofatumumab)
Kesimpta is a targeted, precisely dosed and delivered B-cell therapy that provides the flexibility of self-administration for adults with RMS. It is an anti-CD20 monoclonal antibody (mAb) self-administered by a once-monthly injection, delivered subcutaneously
1,3. Initial doses of Kesimpta are given at Weeks 0, 1 and 2, with the first injection performed under the guidance of a healthcare professional. As shown in preclinical studies, Kesimpta is thought to work by binding to a distinct epitope on the CD20 molecule inducing potent B-cell lysis and depletion
8. The selective mechanism of action and subcutaneous administration of Kesimpta allows precise delivery to the lymph nodes, where B-cell depletion in MS is needed, and preclinical studies have shown that it may preserve the B-cells in the spleen ....

United States , France General , United Kingdom , City Of , Eric Althoff , Isabella Zinck , Thomas Hungerbuehler , Wallstroeme Ofatumumab , Xavier Montalban , Neuroimmunol Neuroinflamm , Samir Shah , Sloan Simpson , Meghan Odonnell , Antonio Ligi , Sclerosis International Federation , Americas Committee For Treatment , Novartis External Communications , Sclerosis Centre Of Catalonia Cemcat , Novartis Pharmaceuticals , Research In Multiple Sclerosis , Committee For Medicinal Products Human Use , Genmab Press , Hebron University Hospital , Drug Administration , European Commission , Novartis Us External Communications ,

Novartis hit by 'COVID-19-related lockdowns' in Q4

Novartis hit by ‘COVID-19-related lockdowns’ in Q4
Sales grew in the quarter but profits fell short of forecasts
Novartis has cited ‘COVID-19-related lockdowns’ for the negative impact on some therapeutic areas in its business, but sales grew despite profits falling short of expectations in Q4.
Despite seeing some impact from COVID-19, Novartis posted an increase in net sales of 3% in Q4 2020 to $12.77bn, compared to the same period last year.
The Swiss pharma company posted a net profit of $2.1bn, which came in under the projected consensus forecast by FactSet that put expected net profit at $2.77bn.
In an update posted along with the Q4 results, Novartis said that ‘COVID-19-related lockdowns’ had negatively impacted certain therapeutic areas. ....

Novartis Pharmaceuticals , Innovative Medicines , Vas Narasimhan , Marie France Tschudin , நோவர்த்திச் மருந்துகள் , புதுமையானது மருந்துகள் , வாஸ் நரசிம்மன் , மேரி பிரான்ஸ் த்ஸ்சுதின் ,

Novartis Explores the Future of Assistive Tech in Multiple Sclerosis

Save this story for later.
Technology that supports the lifestyles of people with disabilities is becoming increasingly sophisticated, but there’s plenty of room for growth. And one of the keys for improving assistive tech is a simple but often overlooked philosophy: working with those who will use the product from the very start.
To support emerging designers helping to improve mobility, accessibility, and daily life for people living with multiple sclerosis, Novartis recently launched the Innovation Prize for Assistive Tech. Specialist tech and accessibility judges from Sequoia, Airbnb and Whill as well as patient experts from Shift.ms, the National Multiple Sclerosis Society and people living with MS evaluated exciting innovations from around the world. “We focused on patient-centered innovation because, as a company, we’ve spent a lot of time trying to understand how we can be a catalyst for technology that is created by and for the MS community,” says Marie-F ....

Maayan Ziv , David Hojah , Novartis Pharmaceuticals , National Multiple Sclerosis Society , Innovation Prize , Marie France Tschudin , Muscular Dystrophy , மாயன் ஜிவ் , நோவர்த்திச் மருந்துகள் , தேசிய பல ஸ்க்லரோசிஸ் சமூகம் , கண்டுபிடிப்பு ப்ரைஸ் , மேரி பிரான்ஸ் த்ஸ்சுதின் , தசை டிஸ்ட்ரோபி ,